332 related articles for article (PubMed ID: 33797691)
41. Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma.
Jacobson CA; Freedman AS
Curr Hematol Malig Rep; 2016 Jun; 11(3):218-23. PubMed ID: 26995595
[TBL] [Abstract][Full Text] [Related]
42. Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma.
Feugier P; Filliatre-Clement L
F1000Res; 2019; 8():. PubMed ID: 30906531
[TBL] [Abstract][Full Text] [Related]
43. An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date.
Yilmaz U; Salihoglu A; Soysal T
Drug Des Devel Ther; 2021; 15():3809-3820. PubMed ID: 34522085
[TBL] [Abstract][Full Text] [Related]
44. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
[TBL] [Abstract][Full Text] [Related]
45. Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.
Cheah CY; Belada D; Fanale MA; Janikova A; Czucman MS; Flinn IW; Kapp AV; Ashkenazi A; Kelley S; Bray GL; Holden S; Seymour JF
Lancet Haematol; 2015 Apr; 2(4):e166-74. PubMed ID: 26687959
[TBL] [Abstract][Full Text] [Related]
46. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
Abramson JS; Ghosh N; Smith SM
Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
[TBL] [Abstract][Full Text] [Related]
47. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F; Fowler NH; Feugier P; Bouabdallah R; Tilly H; Palomba ML; Fruchart C; Libby EN; Casasnovas RO; Flinn IW; Haioun C; Maisonneuve H; Ysebaert L; Bartlett NL; Bouabdallah K; Brice P; Ribrag V; Daguindau N; Le Gouill S; Pica GM; Martin Garcia-Sancho A; López-Guillermo A; Larouche JF; Ando K; Gomes da Silva M; André M; Zachée P; Sehn LH; Tobinai K; Cartron G; Liu D; Wang J; Xerri L; Salles GA;
N Engl J Med; 2018 Sep; 379(10):934-947. PubMed ID: 30184451
[TBL] [Abstract][Full Text] [Related]
48. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Leonard JP; Jung SH; Johnson J; Pitcher BN; Bartlett NL; Blum KA; Czuczman M; Giguere JK; Cheson BD
J Clin Oncol; 2015 Nov; 33(31):3635-40. PubMed ID: 26304886
[TBL] [Abstract][Full Text] [Related]
49. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Wang M; Fowler N; Wagner-Bartak N; Feng L; Romaguera J; Neelapu SS; Hagemeister F; Fanale M; Oki Y; Pro B; Shah J; Thomas S; Younes A; Hosing C; Zhang L; Newberry KJ; Desai M; Cheng N; Badillo M; Bejarano M; Chen Y; Young KH; Champlin R; Kwak L; Fayad L
Leukemia; 2013 Sep; 27(9):1902-9. PubMed ID: 23545991
[TBL] [Abstract][Full Text] [Related]
50. Rituximab maintenance versus retreatment in follicular lymphoma.
Palla AR; Hamadani M
Hematol Oncol; 2013 Dec; 31(4):171-8. PubMed ID: 23044794
[TBL] [Abstract][Full Text] [Related]
51. Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma.
Strati P; Jain P; Johnson RJ; Forbes S; Feng L; Samaniego F; Rodriguez MA; Fayad LE; Hagemeister F; Westin J; Wang M; Neelapu SS; Nastoupil LJ; Fowler NH
Blood; 2021 Feb; 137(8):1124-1129. PubMed ID: 32932518
[No Abstract] [Full Text] [Related]
52. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
53. Copanlisib for the treatment of adults with relapsed follicular lymphoma.
Magagnoli M; Carlo-Stella C; Santoro A
Expert Rev Clin Pharmacol; 2020 Aug; 13(8):813-823. PubMed ID: 32576028
[TBL] [Abstract][Full Text] [Related]
54. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G;
Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345
[TBL] [Abstract][Full Text] [Related]
55. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
Vidal L; Gafter-Gvili A; Leibovici L; Dreyling M; Ghielmini M; Hsu Schmitz SF; Cohen A; Shpilberg O
J Natl Cancer Inst; 2009 Feb; 101(4):248-55. PubMed ID: 19211444
[TBL] [Abstract][Full Text] [Related]
56. Follicular lymphoma: evolving therapeutic strategies.
Kahl BS; Yang DT
Blood; 2016 Apr; 127(17):2055-63. PubMed ID: 26989204
[TBL] [Abstract][Full Text] [Related]
57. Phosphatidylinositol-3-Kinase Inhibition in Follicular Lymphoma.
Lynch RC; Gopal AK
Hematol Oncol Clin North Am; 2020 Aug; 34(4):727-741. PubMed ID: 32586577
[TBL] [Abstract][Full Text] [Related]
58. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Ujjani CS; Jung SH; Pitcher B; Martin P; Park SI; Blum KA; Smith SM; Czuczman M; Davids MS; Levine E; Lewis LD; Smith SE; Bartlett NL; Leonard JP; Cheson BD
Blood; 2016 Nov; 128(21):2510-2516. PubMed ID: 27697771
[TBL] [Abstract][Full Text] [Related]
59. Pros and cons of rituximab maintenance in follicular lymphoma.
Zhang L; Ghielmini M; Cheson BD; Ujjani C
Cancer Treat Rev; 2017 Jul; 58():34-40. PubMed ID: 28628883
[TBL] [Abstract][Full Text] [Related]
60. Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis.
Police RL; Trask PC; Wang J; Olivares R; Khan S; Abbe A; Colosia A; Njue A; Sherril B; Ruiz-Soto R; Kaye JA; Hamadani M
J Oncol Pharm Pract; 2016 Oct; 22(5):666-78. PubMed ID: 26320127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
